Known targets — ChEMBL curated mechanism
BRAFFLT1FLT3FLT4KDRKITPDGFRBRAF1RET
The experimentally established mechanism targets of Sorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.93 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 0.93 |
| ▸ | RET known ✓ | P07949 | 4/20 | 0.93 |
| ▸ | BRAF known ✓ | P15056 | 4/20 | 0.93 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.93 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.93 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.93 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.93 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.93 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.93 |
| ▸ | ABL1 | P00519 | 3/20 | 0.93 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.93 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.93 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.93 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.93 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.93 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.93 |
| ▸ | HTR1A | P08908 | 2/20 | 0.93 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.93 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorafenib SCHEMBL1534040 | 0.98 | RAF1 (0.93) | RAF1KDRRETBRAFAURKB | |
| Sorafenib SCHEMBL29286332 | 0.97 | RAF1 (0.86) | RAF1KDRRETBRAFAURKB | |
| Sorafenib SCHEMBL8218 | 0.96 | RAF1 (1.00) | RAF1KDRRETBRAFAURKB | |
| Sorafenib SCHEMBL29349634 | 0.96 | RAF1 (1.00) | RAF1KDRRETBRAFAURKB | |
| Sorafenib SCHEMBL14739751 | 0.96 | RAF1 (1.00) | RAF1KDRRETBRAFAURKB | |
| Sorafenib SCHEMBL2045626 | 0.96 | RAF1 (0.88) | RAF1KDRRETBRAFAURKB | |
| Sorafenib SCHEMBL1533982 | 0.95 | RAF1 (0.98) | RAF1KDRRETBRAFAURKB | |
| Sorafenib SCHEMBL1533976 | 0.95 | RAF1 (0.98) | RAF1KDRRETBRAFAURKB | |
| Sorafenib SCHEMBL1896610 | 0.95 | RAF1 (0.98) | RAF1KDRRETBRAFAURKB | |
| Sorafenib SCHEMBL18863920 | 0.95 | RAF1 (0.98) | RAF1KDRRETBRAFAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111704574-B | Preparation method of high-purity sorafenib tosylate crystal form III | 齐鲁制药有限公司 | 2024-05-07 | — | — | CN | claimed |
| EP-2440531-A2 | POLYMORPHS OF 4-[4-[[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYLAMINO]PHENOXY]-N-METHYL-PYRIDINE-2-CARBOXAMIDE | Ratiopharm GmbH (DE) | 2012-04-18 | — | — | EP | claimed |
| WO-2010142678-A2 | POLYMORPHS OF 4-[4-[[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYLAMINO]PHENOXY]-N-METHYL-PYRIDINE-2-CARBOXAMIDE | RATIOPHARM GMBH (DE) | 2010-12-16 | — | — | WO | claimed |
| EP-2136844-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | Centre De Recherche Sur Les Biotechnologies Marine (CA) | 2009-12-30 | — | — | EP | claimed |
| WO-2008113177-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) | 2008-09-25 | — | — | WO | claimed |
| CN-116617403-B | Amino acid modified ionic liquid and preparation method and application thereof | 北京大学 | 2026-05-19 | — | — | CN | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-120077067-A | B7-H3 antigen binding molecules | 提克瓦阿洛塞尔私人有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119403808-A | Cyclin-dependent kinase 2 inhibitors for medical treatment | 因西克利克斯生物有限责任公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-119306661-A | Method for simultaneously regulating and controlling novel crystal forms and crystal habit of aripiprazole and novel crystal forms thereof | 广东工业大学 | 2025-01-14 | — | — | CN | disclosed |
| CN-118955475-A | Compound for inhibiting tumor cells and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2024-11-15 | — | — | CN | disclosed |
| CN-118766984-A | Traditional Chinese medicine composition for treating skin reaction of hands and feet | 宁波市中医院 | 2024-10-15 | — | — | CN | disclosed |
| US-8198324-B2 | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof | CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) | 2012-06-12 | — | — | US | disclosed |
| EP-2440531-A2 | POLYMORPHS OF 4-[4-[[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYLAMINO]PHENOXY]-N-METHYL-PYRIDINE-2-CARBOXAMIDE | Ratiopharm GmbH (DE) | 2012-04-18 | — | — | EP | disclosed |
| WO-2011036648-A1 | POLYMORPHS OF SORAFENIB ACID ADDITION SALTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-31 | — | — | WO | disclosed |
| WO-2010142678-A2 | POLYMORPHS OF 4-[4-[[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYLAMINO]PHENOXY]-N-METHYL-PYRIDINE-2-CARBOXAMIDE | RATIOPHARM GMBH (DE) | 2010-12-16 | — | — | WO | disclosed |
| US-20100196496-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | SCF PHARMA INC. (CA) | 2010-08-05 | — | — | US | disclosed |
| EP-2136844-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | Centre De Recherche Sur Les Biotechnologies Marine (CA) | 2009-12-30 | — | — | EP | disclosed |
| US-20090291102-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | SCF PHARMA INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| WO-2008113177-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196496-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | MGLL, PNLIP, FASN | RAF1 1794/4885KDR 2027/4885RET 4499/4885 |
| US-20090291102-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | MGLL, PNLIP, FASN | RAF1 1794/4885KDR 2027/4885RET 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.